KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Intangibles (2018 - 2022)

Historic Intangibles for Esperion Therapeutics (ESPR) over the last 5 years, with Q4 2022 value amounting to $56000.0.

  • Esperion Therapeutics' Intangibles changed 0.0% to $56000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $56000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $56000.0 for FY2022, which is 0.0% changed from last year.
  • Latest data reveals that Esperion Therapeutics reported Intangibles of $56000.0 as of Q4 2022, which was down 0.0% from $56000.0 recorded in Q4 2021.
  • In the past 5 years, Esperion Therapeutics' Intangibles ranged from a high of $56000.0 in Q1 2018 and a low of $56000.0 during Q1 2018
  • Over the past 5 years, Esperion Therapeutics' median Intangibles value was $56000.0 (recorded in 2018), while the average stood at $56000.0.
  • Within the past 5 years, the most significant YoY rise in Esperion Therapeutics' Intangibles was 0.0% (2019), while the steepest drop was 0.0% (2019).
  • Quarter analysis of 5 years shows Esperion Therapeutics' Intangibles stood at $56000.0 in 2018, then changed by 0.0% to $56000.0 in 2019, then changed by 0.0% to $56000.0 in 2020, then changed by 0.0% to $56000.0 in 2021, then changed by 0.0% to $56000.0 in 2022.
  • Its last three reported values are $56000.0 in Q4 2022, $56000.0 for Q4 2021, and $56000.0 during Q4 2020.